Table 3 Cost-effectiveness results from one-way deterministic sensitivity analyses
Scenario | Infliximab | Ciclosporin | Incremental QALY (Ciclos-Inflx) | Incremental Cost (Ciclos-Inflx) | ICER/Cost-effectiveness | ||
|---|---|---|---|---|---|---|---|
Costs (£) | QALYs | Costs (£) | QALYs | ||||
10% reduction in inflx. price | 33,331 | 9.106 | 26,793 | 9.816 | 0.710 | -6,538 | Ciclsoporin dominates |
20% reduction in inflx. price | 32,477 | 9.106 | 26,793 | 9.816 | 0.710 | -5,684 | Ciclsoporin dominates |
50% reduction in inflx. price | 29,914 | 9.106 | 26,793 | 9.816 | 0.710 | -3,121 | Ciclsoporin dominates |
70% reduction in inflx. price | 28,206 | 9.106 | 26,793 | 9.816 | 0.710 | -1,413 | Ciclsoporin dominates |
80% reduction in inflx. price | 27,352 | 9.106 | 26,793 | 9.816 | 0.710 | -559 | Ciclsoporin dominates |
10% reduction in ciclos. utility | 34,185 | 9.106 | 26,793 | 9.708 | 0.602 | -7,392 | Ciclosporin dominates |
10% increase in ciclos. utility | 34,185 | 9.106 | 26,793 | 9.913 | 0.807 | -7,392 | Ciclsoporin dominates |
10% reduction in inflx. utility | 34,185 | 8.951 | 26,793 | 9.816 | 0.865 | -7,392 | Ciclsoporin dominates |
10% increase in inflx. utility | 34,185 | 9.262 | 26,793 | 9.816 | 0.554 | -7,392 | Ciclosporin dominates |
Fixed transition probability (TP) | 44,829 | 9.283 | 41,005 | 9.721 | 0.438 | -3,824 | Ciclsoporin dominates |
10-year time horizon (time dependent TP) | 28,163 | 6.315 | 20,376 | 6.713 | 0.398 | -7,787 | Ciclsoporin dominates |
10-year time horizon (Fixed TP) | 31,326 | 6.198 | 24,963 | 6.475 | 0.277 | -6,363 | Ciclsoporin dominates |
Beyond 2-yr trial follow-up | 15,748 | 7.613 | 15,103 | 8.219 | 0.606 | -645 | Ciclsoporin dominates |